B44.0 Invasive pulmonary aspergillosis

Name of the Condition

• Invasive pulmonary aspergillosis

Summary

Invasive pulmonary aspergillosis is a severe fungal infection of the lungs caused by Aspergillus species. It occurs when the fungus invades lung tissue and blood vessels, typically in immunocompromised individuals. The condition can progress rapidly and may lead to respiratory failure or systemic spread if not treated promptly.

Causes

The infection is caused by Aspergillus species, which are common environmental molds. Spores are inhaled into the lungs, where they can germinate and invade tissue in hosts with weakened immune systems. Unlike allergic or non-invasive forms, invasive disease involves tissue invasion and potential vascular involvement.

Risk Factors

• Immunocompromised states, such as prolonged neutropenia, organ transplantation, or advanced HIV.
• Chronic lung diseases, including cystic fibrosis, tuberculosis, or prior lung damage.
• High-dose corticosteroid therapy or other immunosuppressive treatments.
• Prolonged hospitalization, especially in intensive care settings.
• Environmental exposure to high concentrations of Aspergillus spores.

Symptoms

• Persistent cough, often with sputum or hemoptysis (coughing up blood).
• Fever, chest pain, or shortness of breath.
• Fatigue, weight loss, or malaise.
• Worsening respiratory function in at-risk patients.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory testing. Chest imaging (e.g., CT scans) may show nodules, cavities, or the "halo sign." Microbiological confirmation is obtained through sputum or bronchoalveolar lavage cultures, or tissue biopsy. Serum biomarkers like galactomannan may support the diagnosis, but definitive proof requires fungal identification.

Treatment Options

Treatment typically includes antifungal medications, such as voriconazole or isavuconazole, as first-line therapy. Amphotericin B may be used in severe cases. Duration of therapy depends on the extent of infection and immune status. Adjunctive measures, like reducing immunosuppression, may be necessary in transplant recipients.

Prognosis and Follow-Up

Prognosis varies based on the patient's immune status and timeliness of treatment. Early intervention improves outcomes, but mortality remains high in severely immunocompromised individuals. Follow-up includes monitoring for treatment response, recurrence, or complications, with repeat imaging or biomarker testing as needed.

Complications

• Respiratory failure due to lung tissue destruction.
• Hemoptysis from vascular invasion.
• Dissemination to other organs (e.g., brain, kidneys).
• Chronic lung damage or fibrosis in survivors.

Lifestyle & Prevention

• Avoid environments with high mold exposure (e.g., construction sites, decaying vegetation).
• Use air filtration in high-risk settings.
• Maintain optimal immune function through vaccination and managing underlying conditions.
• Promptly address respiratory symptoms in immunocompromised patients.

When to Seek Professional Help

Seek immediate medical attention if you experience persistent cough, fever, chest pain, or hemoptysis, especially if you have risk factors like immunosuppression or chronic lung disease. Early evaluation is critical for invasive pulmonary aspergillosis.

Tips for Medical Coders

Document the presence of invasive fungal disease, including confirmation of Aspergillus species and pulmonary involvement. Note any underlying immunocompromising conditions, as these support the diagnosis. Ensure clinical correlation with imaging or laboratory findings to validate code assignment.